Bio Pharma Dive
JANUARY 2, 2022
Biotech stocks ended 2021 in a slump. But positive results from eagerly anticipated studies in breast cancer, schizophrenia and Alzheimer's disease could help turn the sector's fortunes around.
World of DTC Marketing
JANUARY 4, 2022
(Stat News) Today, a study followed 380 patients being treated at community oncology groups across the U.S. after they were diagnosed with metastatic colon cancer. They told the researchers that insurance didn’t protect them from serious money problems. While 98% of them had insurance, 71% fell deeper into debt, took out a new loan, sold or refinanced a home, or experienced at least a 20% decline in income — or a combination of these over the year they answered quarterly surveys.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
JANUARY 5, 2022
The test is a technological first in determining the metastatic status of a cancer without using prior insight of the primary cancer presented.
pharmaphorum
JANUARY 4, 2022
The global R&D pipeline is dominated by potential treatments in oncology and this is also where the investment is flowing. This doesn’t look like changing moving into the future, the main challenge will be managing to use this money to create a proportionate number of approved treatments and ensuring an early diagnosis for patients in the area. In this article, Ben Hargreaves explores how advances in technology could address these challenges.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
JANUARY 7, 2022
Amylyx, CinCor and Vigil raised about $480 million combined, a sign of continued investor interest in biotech IPOs. But industry analysts expect fewer and smaller offerings in 2022 due to investor fatigue from high valuations.
World of DTC Marketing
JANUARY 1, 2022
Yes, there will be changes in healthcare in the coming years but put away the thoughts that telehealth and wearable devices will revolutionize healthcare. More and more patients demand a level of service they want with the increased costs of health insurance premiums. Here are things I believe are more realistic. 1ne: The value proposition of prescription drugs still outweighs potential side effects – Wegovy’s demand quickly exceeded supply after the FDA approved once-weekly semaglut
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
JANUARY 5, 2022
A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. The new vaccine differs from the currently approved shots because it delivers antigens for both the spike protein and other proteins found in SARS-CoV-2.
Bio Pharma Dive
JANUARY 5, 2022
The pharma company, already partnered with BioNTech on vaccines for COVID-19 and influenza, will pay $225 million upfront to further expand its work with the German biotech.
World of DTC Marketing
JANUARY 3, 2022
The estimated numbe r of annual deaths attributable to obesity among U.S. adults is approximately 280,000 based on H.R.s from all subjects and 325,000 based on H.R.s from only nonsmokers and never-smokers. As the N.Y. Times recently reported, estimates of the medical cost of adult obesity in the United States (U.S.) range from $147 billion to nearly $210 billion per year.
Pharma Mirror
JANUARY 4, 2022
CPhI Predictions for 2022: high manufacturing demand to constrain global ingredients, partnering options and available CDMO capacity. Continued stellar growth in pharma sales and innovation bode well for supply side companies and CDMOs Amsterdam: CPhI Worldwide releases its beginning of year pharma market predictions for 2022 combining research from over 350 pharma executives and expert views from 10 CPhI contributors.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Times
JANUARY 7, 2022
The platform integrates primary human tissue samples into early target and drug discovery research.
Bio Pharma Dive
JANUARY 5, 2022
The first three months of 2022 could bring clearances for a new type of immunotherapy and a first-of-its kind HIV drug as well as mark the start of a price battle in oncology.
World of DTC Marketing
JANUARY 7, 2022
GoodRx promotes itself as a company that allows you to compare drug prices and find coupons at over 60,000 pharmacies across the country, but actually, most pharmacists hate it. When they say compare prescription drug prices, they mean the cost of a prescription if you aren’t using insurance. And advertising? Uh, no. GoodRx makes money in two main ways: Advertisements on their site and a percentage fee every time a GoodRx coupon is used at the pharmacy.
Pharma Mirror
JANUARY 3, 2022
Healthcare professionals who comply with the Health Insurance Portability and Accountability Act (HIPAA) will benefit by removing the risk of breaching the HIPAA rules. Their patients would feel secure with them. They won’t be at risk of losing their license. They will also benefit from the continued business they’ll get from hospitals that require compliant professionals.
Pharma Times
JANUARY 7, 2022
With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer in the UK.
Bio Pharma Dive
JANUARY 5, 2022
Inflation in 2021 may have offered drugmakers a catalyst for taking slightly bigger increases on a list price basis. But rebates to insurers are still keeping net price rises lower.
pharmaphorum
JANUARY 7, 2022
AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months. In the latest deal, the pharma group is paying $30 million upfront with another $730 million in milestone’s for global rights to Neurimmune’s NI006, a drug in early-stage clinical for cardiomyopathy, a progressive and fatal complication affecting some patients with ATTR.
Scienmag
JANUARY 6, 2022
For more than 150 years, Volutella blight has been one of the most common diseases of the loved and iconic boxwood plant as well as other plants in the family, including pachysandra and sarcococca. Despite its presence on every continent except Antarctica, the disease can be hard to identify. To help with diagnosis, a group […].
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
JANUARY 6, 2022
Testing rules for COVID-19 are set to be eased for those who test positive on a lateral flow test but are asymptomatic.
Bio Pharma Dive
JANUARY 6, 2022
For $50 million, Lilly has secured rights to a technology that's meant to transport nucleic acid therapies in a way that's more targeted and better tolerated than other methods.
pharmaphorum
JANUARY 6, 2022
We spoke with Tanja Dowe, ahead of the annual J.P. Morgan Health Care Conference 2022, about radical innovation in healthcare, including the potential of digital solutions to diagnose disease earlier, using digital therapeutics or preventive digital solutions more efficiently, and making use of technologies that result in accelerated drug discovery and development.
BioPharma Reporter
JANUARY 6, 2022
Pfizer and BioNTech, in what will be the third mRNA vaccine collaboration between the two companies, are teaming up on the development of a potential first mRNA-based vaccine for the prevention of shingles.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Times
JANUARY 6, 2022
The companies share the goal of furthering knowledge around GPCR biology in immune cells in order to better understand a range of immune system disorders.
Bio Pharma Dive
JANUARY 4, 2022
The company spent $60 million to secure global rights to an experimental drug developed by Ionis Pharmaceuticals to treat spinal muscular atrophy.
pharmaphorum
JANUARY 7, 2022
It’s no secret that fertility treatment is expensive and has a low success rate, placing a big financial and emotional burden on would-be parents. Now, a Canadian startup aims to tackle that problem though the use of artificial intelligence. Toronto-based Future Fertility has developed an AI called Violet that it says can predict the viability of cryopreserved eggs used for in vitro fertilisation (IVF), making sure that those most likely to result in a successful procedure.
XTalks
JANUARY 5, 2022
Amid skyrocketing cases of Omicron across the US and worldwide, the US Food and Drug Administration (FDA) has made a couple of amendments to the emergency use authorization (EUA) of Pfizer/BioNTech’s COVID-19 vaccine, including a booster dose for individuals between 12 and 15 years of age. The offering of a third dose for this age group now makes all individuals 12 years of age and older eligible for a single booster.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
JANUARY 4, 2022
Pfizer’s Paxlovid has a success rate of nearly 90% as a prophylaxis treatment against severe COVID-19 when administered shortly after the patient has been infected with the virus.
Bio Pharma Dive
JANUARY 4, 2022
The biotech's treatment was one of the furthest along in testing for Fabry, a rare inherited disease that's become a target for gene therapy developers.
pharmaphorum
JANUARY 5, 2022
The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC) whose tumours overexpress c-Met.
XTalks
JANUARY 5, 2022
Have you ever been asked to join a company’s talent community during a job search? If so, then you must know that these talent communities are becoming a vital recruitment strategy for employers. . A talent community is a digital network of potential employees that have previously expressed interest in certain roles from your organization. Many companies have built highly successful talent communities and benefited from their advantages for recruitment. .
Expert insights. Personalized for you.
363 
Let's personalize your content